Premium
Infusion of dendritic cells pulsed with HLA‐A2‐specific prostate‐specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone‐refractory metastatic disease
Author(s) -
Murphy G.P.,
Tjoa B.A.,
Simmons S.J.,
Jarisch J.,
Bowes V.A.,
Ragde H.,
Rogers M.,
Elgamal A.,
Kenny G.M.,
Cobb O.E.,
Ireton R.C.,
Troychak M.J.,
Salgaller M.L.,
Boynton A.L.
Publication year - 1999
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/(sici)1097-0045(19990101)38:1<73::aid-pros9>3.0.co;2-v
Subject(s) - prostate cancer , medicine , prostate , prostate specific antigen , prostatic acid phosphatase , oncology , immune system , cancer , urology , gastroenterology , immunology
BACKGROUND A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA‐A2‐specific PSMA peptides (PSM‐P1 and ‐P2). This report describes thirty three subjects with hormone‐refractory metastatic prostate cancer without prior vaccine therapy history who were evaluated and reported as a group. METHODS All subjects received six infusions of DC pulsed with PSM‐P1 and ‐P2 at six week intervals. Clinical monitoring was conducted pre‐, during, and post‐ phase II study. Data collected include: complete blood count, bone and total alkaline phosphatase, prostate markers, physical examination, performance status, bone scan, ProstaScint® scan, chest x‐ray, as well as assays to monitor cellular immune responses. RESULTS Six partial and two complete responders were identified in the phase II study based on NPCP criteria, plus 50% reduction of prostate‐specific antigen (PSA), or resolution in previously measurable lesions on ProstaScint® scan. CONCLUSIONS Over 30% of study participants in this group showed a positive response at the conclusion of the trial. This study suggested that DC‐based cancer vaccines may provide an alternative therapy for prostate cancer patients whose disease no longer responds to hormone therapy. Prostate 38:73–78, 1999. © 1999 Wiley‐Liss, Inc.